Reply Journal of Allergy and Clinical Immunology

Slides:



Advertisements
Similar presentations
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Allergen immunotherapy: A practice parameter third update
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Pharmacologic rationale for treating allergic and nonallergic rhinitis
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Dennis K. Ledford, MD, Sally Wenzel, MD 
David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Dana V. Wallace, MD, Mark S. Dykewicz, MD, David I
Is 9 more than 2 also in allergic airway inflammation?
Desensitization to Chemotherapeutic Agents
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Allergic skin diseases
An Infant with Atopic Dermatitis and Itching After Ingestion of Milk
Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract  Sheila M. Amar, MD, Ronald.
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Allergy testing in predicting outcome of open food challenge to peanut
A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema 
Treatment of chronic autoimmune urticaria with omalizumab
Nonadherence to Asthma Treatment: Getting Unstuck
Peter M. Wolfgram, MD, David B. Allen, MD 
Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA 
Reply Journal of Allergy and Clinical Immunology
Phillip Lieberman, MD, Michael Tankersley, MD 
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects  William Busse, MD, Sheldon Spector, MD, Karin Rosén,
Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation  Leif Bjermer, MD  Journal of Allergy.
News & Notes Journal of Allergy and Clinical Immunology
Phillip Lieberman, MD, David Golden, MD 
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
Biosimilars and drug development in allergic and immunologic diseases
A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity  Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,
Claus Bachert, MD, PhD, Cezmi A. Akdis, MD 
What is an “eosinophilic phenotype” of asthma?
Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants  Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,
Cephalosporin Side Chain Cross-reactivity
Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis  Stephen R. Durham,
H. William Kelly, PharmD  Journal of Allergy and Clinical Immunology 
Personalized asthma therapy in blacks—the role of genetic ancestry
Autophagy: Nobel Prize 2016 and allergy and asthma research
News & Notes Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
Advances in the approach to the patient with food allergy
Diagnosis and management of early asthma in preschool-aged children
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years  Ronald Dahl, MD,
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet  Stephen.
One step forward, 2 steps back: The enigma of preschool wheeze
Risk of oral food challenges
Reply Journal of Allergy and Clinical Immunology
The Editors' Choice Journal of Allergy and Clinical Immunology
Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A
A randomized trial of methotrexate versus azathioprine for severe atopic eczema  Mandy Elvira Schram, MD, Evelien Roekevisch, MD, Mariska Maria Geertruida.
Measles and immunomodulation
Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines.
Macrolide antibiotics and asthma treatment
Asthma: The past, future, environment, and costs
Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials 
Environmental factors and eosinophilic esophagitis
News & Notes Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
The GILL study: Glycerin-induced local reactions in immunotherapy
Advances in pediatric asthma in 2007
Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule 
Natural history of cow’s milk allergy
Primary prevention of asthma and allergy
Itching as a systemic disease
Presentation transcript:

Reply Journal of Allergy and Clinical Immunology Michael Blaiss, MD, Harold S. Nelson, MD, Stephen R. Durham, MD, Ronald Dahl, MD, Albrecht Bufe, MD  Journal of Allergy and Clinical Immunology  Volume 128, Issue 2, Pages 430-432 (August 2011) DOI: 10.1016/j.jaci.2011.04.053 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Pooled data from 4 trials2-5 assessed post hoc (n = 1671). A, Symptom scores for the entire placebo group (n = 840) and for the subgroup of subjects receiving active treatment who did not report any treatment-related adverse events (TRAE; n = 139). B, Symptom scores for subjects receiving active treatment who did not report any of the 4 most common adverse events (AEs; oral pruritus, throat irritation, mouth edema, and ear pruritus; n = 387) and for subjects with at least 1 of the 4 most common local reactions (n = 444). Journal of Allergy and Clinical Immunology 2011 128, 430-432DOI: (10.1016/j.jaci.2011.04.053) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions